EMEA approves abiraterone acetate for treatment of mCRPC


Last Friday the European Medicines Agency (EMEA) gave approval for the marketing of abiraterone acetate (Zytiga™) for the treatment of metastatic, castration-resistant prostate cancer in men who have already progressed after treatment with docetaxel-based chemotherapy.

Abiraterone acetate will still need approval from the European Commission before it can actually be prescribed in the EU nations, but such approval usually occurs within a few months of a decision by EMEA. And of course an approval will still be followed by country-specific negotiations about the cost of abiraterone acetate before it can actually be covered under the national health systems of nations like the UK and Germany.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

Follow

Get every new post delivered to your Inbox.

Join 1,119 other followers